Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults. Commercial arrangements There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact market_access@eisai.net (for lenvatinib) and keiron.hughes@msd.com (for pembrolizumab) for details.